Severe pulmonary toxicity associated with intraperitoneal mitomycin C: a warning from two cases of CRS + HIPEC in different institutions
Abstract Mitomycin C (MMC) is commonly used in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies. While myelosuppression is a known complication, pulmonary toxicity is rare. We present here two cases of acute respiratory distress syndrome (ARDS) following intraper...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/25550 |
| Acceso en línea: | https://hdl.handle.net/20.500.13003/25550 |
| Access Level: | acceso abierto |
| Palabra clave: | Hyperthermic Intraperitoneal Chemotherapy Mitomycin Toxicity Quimioterapia Intraperitoneal Hipertérmica Mitomicina Toxicidad colorectal cancer cytoreductive surgery hyperthermic intraperitoneal chemotherapy mitomycin C toxicity |
| Sumario: | Abstract Mitomycin C (MMC) is commonly used in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies. While myelosuppression is a known complication, pulmonary toxicity is rare. We present here two cases of acute respiratory distress syndrome (ARDS) following intraperitoneal MMC during CRS-HIPEC. A 61-year-old female developed rapid respiratory failure 36 h postoperatively and died from multiorgan failure; autopsy revealed systemic endothelial injury. A 72-year-old female with pseudomyxoma peritonei developed ARDS on postoperative day 4. After corticosteroid treatment, her condition improved. These cases highlight the risk of severe pulmonary toxicity from intraperitoneal MMC. Clinicians should consider MMC-induced ARDS in the differential diagnosis of postoperative respiratory failure following HIPEC. |
|---|